Keywords: Ardea Biosciences, Mayer, Milestone, Nexavar, BAY 86-9766, Liver cancer

Ardea earns $15 million milestone from Bayer as BAY 86-9766 moves into Ph II

Article | 11 January 2011

Print This

Ardea Biosciences (Nasdaq: RDEA) saw its shares leap 9.9% to $28.66, after saying that it has earned a $15 million milestone payment from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in